SPLENECTOMY VERSUS CLADRIBINE THERAPY IN HAIRY CELL LEUKEMIA PATIENTS: A CLINICAL TRIAL

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

JALAEE KHOO H.; KEIHANI M.; YOUSEFIAN A.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ) Year:2009 | Volume:67 | Issue:8 Page(s): 549-555

Download Full-Text

Persian Verion

View:

999

Download:

Cites:

Information Journal Paper

Title

SPLENECTOMY VERSUS CLADRIBINE THERAPY IN HAIRY CELL LEUKEMIA PATIENTS: A CLINICAL TRIAL

Author(s)

JALAEE KHOO H. | KEIHANI M. | YOUSEFIAN A. | Issue Writer Certificate

Keywords

HAIRY CELL LEUKEMIAQ2

CLADRIBINEQ3

SPLENECTOMYQ3

Abstract

Background: HAIRY CELL LEUKEMIA (HCL) is a rare B-cell neoplasm that comprise approximately 2% of all lymphoid leukemias. Over the past 20 years SPLENECTOMY was the only effective therapy but with the advent of purine analogues such as CLADRIBINE, SPLENECTOMY has been limited to certain situations. After CLADRIBINE therapy most patients achieve complete and durable remission. The aim of this study was to compare effectiveness of SPLENECTOMY and CLADRIBINE in Iranian patients with HCL and also to evaluate the clinical and laboratory features of patients at diagnosis.Methods: 50 patients with the diagnosis of HCL enrolled to our study.The male to female ratio was 3:1, and the median age at diagnosis was 50 years.After diagnosis 20 (40%) and 12 (24%) of patients had SPLENECTOMY and CLADRIBINE therapy respectively. The reminder of patients were treated with both SPLENECTOMY and CLADRIBINE.Results: The most common clinical findings were splenomegaly (98%) and fatigue (80%) respectively. Leucopenia and anemia was present in 96% and 80% patients in order.88.6% and 55.5% of patients achieved complete remission after CLADRIBINE therapy and SPLENECTOMY respectively. After CLADRIBINE therapy and SPLENECTOMY relapse occurred in 10% and 74% of the patients.Conclusions: Our finding are comparable with previous studies and show that CLADRIBINE induces complete and durable remission in most HAIRY CELL LEUKEMIA patients and should be considered as first line therapy. SPLENECTOMY should be performed in certain cases such as spleen rupture.

Cites

No record.

References

No record.

Cite

APA: Copy

JALAEE KHOO, H., KEIHANI, M., & YOUSEFIAN, A.. (2009). SPLENECTOMY VERSUS CLADRIBINE THERAPY IN HAIRY CELL LEUKEMIA PATIENTS: A CLINICAL TRIAL. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), 67(8), 549-555. SID. https://sid.ir/paper/38451/en

Vancouver: Copy

JALAEE KHOO H., KEIHANI M., YOUSEFIAN A.. SPLENECTOMY VERSUS CLADRIBINE THERAPY IN HAIRY CELL LEUKEMIA PATIENTS: A CLINICAL TRIAL. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ)[Internet]. 2009;67(8):549-555. Available from: https://sid.ir/paper/38451/en

IEEE: Copy

H. JALAEE KHOO, M. KEIHANI, and A. YOUSEFIAN, “SPLENECTOMY VERSUS CLADRIBINE THERAPY IN HAIRY CELL LEUKEMIA PATIENTS: A CLINICAL TRIAL,” TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), vol. 67, no. 8, pp. 549–555, 2009, [Online]. Available: https://sid.ir/paper/38451/en

Related Journal Papers